Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis. Skin biopsy revealed multiple superficial thrombosed vessels with focal epidermal necrosis as well as prominent interstitial mucinosis. Treatment with low-molecular-weight heparin followed by a heparinoid resulted in slow healing of the ulcers but also allowed the subcutaneous interferon injections to be continued.
Wells
Jillian
J
Department of Dermatology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Kossard
Steven
S
McGrath
Michael
M
D034861:Abdominal Wall; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D017520:Mucinoses / Q000139:chemically induced* / Q000473:pathology; D009103:Multiple Sclerosis / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy; D016896:Treatment Outcome; D014456:Ulcer / Q000139:chemically induced* / Q000473:pathology
D000276:Adjuvants, Immunologic; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006497:Heparan Sulfate; D000068576:Interferon beta-1b; D016899:Interferon-beta; C035838:danaparoid